Few people starting tamoxifen require an ophthalmic evaluation during the following year.
Commentary|Articles|September 2, 2026
Eichenbaum: KSI-101 could become first-line in uveitic macular edema
Author(s)Kassi Filkins, David A. Eichenbaum, MD, FASRS
Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.
Advertisement
Advertisement
Macular edema secondary to non-infectious inflammation (MESI) remains one of the more difficult presentations in the retina clinic, where treatment still leans heavily on corticosteroids and their well-known cataract and intraocular pressure trade-offs; additionally, no intravitreal biologic is yet FDA-approved specifically for the indication.
Related to this article
Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.
The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.
Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.
Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.
Advertisement
Advertisement